Skip to content

Immediate Pain Relieving Effects of Sinbaro-3 for Low Back Pain

Immediate Pain Relieving Effects of Sinbaro-3 Pharmaco-acupuncture in Low Back Pain Patients; A Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02196129
Enrollment
60
Registered
2014-07-21
Start date
2014-07-31
Completion date
2014-11-30
Last updated
2018-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herniated Intervertebral Disc, Low Back Pain Without Radiculopathy, Low Back Pain With Radiculopathy

Keywords

low back pain, pharmacoacupuncture, sinbaro-3

Brief summary

The purpose of this study is to investigate the immediate pain relieving effects of sinbaro-3 pharmaco-acupuncture in patients with low back pain admitted for inpatient care

Detailed description

60 patients with LBP with moderate to severe pain(NRS\>6) were randomly allocated to 2 groups. The experimental group was treated with sinbaro-3 pharmacoacupuncture and the control group was treated with Hwangryun pharmacoacupuncture. All administrations were limited to 1 session, and comparisons of measurements were made before and after treatment. Primary outcomes were measured using the VAS scale. Post-treatment follow-up will be performed to measure primary outcomes at 30 minutes, 2hours, 4hours, and 6 hours after treatment. Before and after each measurement, the patients are asked to stand up and rotate their torso. At termination of the study, satisfaction levels of the patient's current status will also be collected.

Interventions

DRUGSinbaro-3

1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain

DRUGHwangryun

1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain

Sponsors

Jaseng Hospital of Korean Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* Patients admitted to a Korean Medicine hospital for low back pain with or without radiculopathy * Age between 18 and 69 * NRS score of \>6 on the day of the intervention * Voluntary participation with written consent given to study consent form

Exclusion criteria

* Diagnosis of serious disease(s) which are possible causes of back pain such as malignancy, vertebral fracture, spinal infection, inflammatory spondylitis, cauda equina compression, etc. * Prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, Alzheimer's disease, epilepsy, etc. * Progressive neurologic deficit(s) or concurrent severe neurological symptoms * Unsuitable for or at risk of complications from acupuncture treatment such as patients with clotting disorders, severe diabetes with risk of infection, serious cardiovascular disease, or undergoing anticoagulant treatment, etc. * Under prescription of corticosteroids, immuno-suppressant drugs, psychiatric medicine, or other medication considered unsuitable for subjects by the researcher * Experience of gastroenteric complications after taking NSAIDs or currently undergoing treatment for digestive disorders * During pregnancy or suspected pregnancy * Subjects considered unsuitable for clinical trial by the researcher

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue ScaleAt baselineThe patient is asked to stand up and roatate the torso to the left and right, then asked to mark on the visual analogue scale the intensity of the pain they are experiencing

Secondary

MeasureTime frameDescription
Satisfaction levels6hrs following treatment7-point Likert scale

Other

MeasureTime frameDescription
Expected treatment effectsAt baselineThe patients are asked to reply how effective they think the treatment is going to be on a 6-point Likert-scale

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026